By modulating the PD-1 axis, treatment with Cetuximab may lead to a decrease in the therapeutic effect of immunotherapies (PD-1 inhibitors) in patients with recurrent cSCC [104]. The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.